FDA, drug development, biobusiness

Biotechs have developed enzyme replacements and genetically modified probiotics to treat patients with the rare metabolic disorder.

A report finds that new medications still take about 12 years to go from patent to patient.

Among a subset of US Food and Drug Administration regulators who leave the agency, more than half go to work for pharmaceutical companies, researchers report.

Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.